The early experiments that led to the purinergic signalling hypothesis will be described. The main conceptual steps during the development of the field will follow. These include: ATP as a cotransmitter; purinergic synaptic transmission in ganglia and the CNS; the cloning and characterization of receptors for ATP and adenosine; immunostaining of receptor subtypes on neuronal and non-neuronal cells; purinergic signalling in plants; ATP release from all cells by mechanical stimulation; dual control of vascular tone by ATP via perivascular nerves and endothelial cells; and ectonucleotidases. The recent focus has been on the pathophysiology and therapeutic potential of purinergic signalling. This includes clopidogrel, a P2Y 12 receptor antagonist for stroke and thrombosis; a long-lasting P2Y 2 receptor agonist for dry eye; the exploration of P2X3 receptor antagonists for chronic cough, lower urinary tract disorders, visceral pain and hypertension; the use of P2X7 receptor antagonists for inflammatory and neurodegenerative diseases; the development of A 2A receptor antagonists for Parkinson's disease and agonists for supraventricular tachycardia; the involvement of purinergic signalling in the mechanism underlying acupuncture.
Lead optimisation of a P2X1-purinoceptor antagonist tool compound for non-hormonal male contraception Approximately one third of the 200 million pregnancies around the world each year are unintended (WHO). While present contraceptive methods are effective, a large majority of men welcome the idea of additional methods of male contraception other than condoms. In particular, an orally viable and reversible male contraceptive remains to be developed. We have a validated biological strategy that dual genetic deletion of α 1A -adrenoceptors and P2X1-purinoceptors in male mice blocks sympathetically mediated sperm transport through the vas deferens during the emission phase of ejaculation. A number of orally available selective α 1A -adrenoceptor antagonists, such as tamsulosin, have been shown in clinical studies to decrease ejaculate volume. However, most of the selective P2X1-purinoceptor antagonists are polar compounds possessing metabolic stability issues. We recently uncovered a compound disclosed in a patent with data suggesting it can antagonize P2X1-purinoceptors at sub-micromolar levels in a cell-based assay. Its potential for functionalisation serves as a suitable starting point for optimisation as a tool compound. This project involves a medicinal chemistry approach to identify a suitable P2X1-purinoceptor antagonist to use in combination with tamsulosin as a male contraceptive. Currently, we have established a first-generation structure-activity relationship of our compound class, with our best compound having an IC 50 of 31 μM in electric field stimulated isolated rat vas deferens preparations and a concentration-dependent antagonism at the P2X1-purinoceptor (K B = 17.3 μM). Our current efforts are focused on identifying more potent compounds with suitable pharmacokinetic properties to progress to in vivo mice models.
Structural basis for binding of antagonists, including a novel adamantanyl benzamide compound, to the human P2X7 receptor The P2X7 receptor is an ATP-gated ion channel that is formed by three multi-pass cell membrane protein subunits. P2X7 activation induces the opening of a non-selective cation channel and cellular responses including cytokine secretion and surface molecule shedding. P2X7 is a potential target for the treatment of inflammatory and neurodegenerative diseases, and antagonists have shown efficacy in animal models. However, these results have not translated to human trials and development of new inhibitors is hampered by the inability to elucidate the crystal structure of human P2X7. In panda P2X7, a drug-binding pocket containing critical amino acids conserved in human P2X7 has been identified. We studied the effect of mutating these amino acids in human P2X7 by A804598 and JNJ47965567, and a novel inhibitor, SW139. Mutations F95A, M105A and V312A made P2X7 more resistant to inhibition by A804598 and JNJ47965567. Unexpectedly, F95A made the human receptor more susceptible to inhibition by SW139, while the other two mutations made it more resistant. This study showed that in human and panda P2X7, the same amino acids are involved in interactions between the receptor and inhibitors. Understanding interactions between antagonists and P2X7 will advance development of more potent and specific P2X7 antagonists.
Inhibition of pannexin-1 channel alleviates extracellular ATPinduced P2X7R activation-dependent large pore-formation in bladder urothelial cells ATP release is a well-known phenomenon mediated by pannexin-1 channels during inflammation, apoptosis or cell damage. It has been shown that increased level of extracellular ATP plays an important role in initiating inflammatory responses via P2X7 receptor (P2X7R) signalling. This study aimed to investigate the pore formation activity induced by P2X7R activation on bladder urothelial cells and to determine if there is a crosstalk between P2X7R and pannexin-1. The expression of P2X7R and pannexin-1 in porcine bladder tissue and cultured urothelial cells were examined by immunohistochemistry. ATP and the selective P2X7R agonist BzATP induced pore-formation was explored in porcine bladder urothelial cells and the RT4 cell line through the uptake of YO-PRO-1 (2 μM, 630 Da). Dense P2X7R and pannexin-1 were primarily expressed in the urothelial layer of the porcine bladder. In primary cultured porcine bladder urothelial cells and the RT4 cell line, YO-PRO-1 uptake was significantly enhanced by high concentrations of , and the effect was completely abolished or greatly reduced following co-treatment with the selective P2X7R antagonists AZ11645373 and A-804598. In porcine urothelial cells, increased YO-PRO-1 uptake stimulated by ATP and BzATP (both 0.3 M) was alleviated by 10 Panx1 (100 μM), a selective pannexin-1 inhibitor. Dense expression of P2X7R and pannexin-1 in the bladder urothelium under normal conditions indicates that P2X7R and pannexin-1 may be involved in regulating bladder physiological functions. Our study is the first report demonstrating P2X7R-dependent pore-formation and the crosstalk between P2X7R and pannexin-1 channel in the bladder. Purinergic signalling in the inner ear has been of substantial interest since the late '80s, when Ca 2+ imaging and patchclamp revealed a range of physiological actions of extracellular ATP on cochlear sensory hair cells. Both adenosine-P1 receptor and ATP-P2 receptor functions where discriminated with pharmacology, and in situ hybridization and immunocytochemistry probes resolved the breadth of the purinergic signalling in the cochlea, including the ATP release pathways, ATP hydrolysis, and P1 and P2 receptor expression. P2X2 receptors were immediately identified as a prominent component of cochlear purinergic signalling machinery, and this was investigated using the P2rx2-null mouse line, with the surprising finding that unlike wildtype mice, these knockout (KO) mice failed to exhibit adaptation of their hearing with sustained elevation of background noise. This humoral hearing desensitization mechanism was found to be critical for long-term preservation of hearing. The KO mice were vulnerable to noise-and agerelated hearing loss. The connection between reduction in purinergic hearing adaptation and vulnerability to hearing loss has now been confirmed in many families in China, Europe and Japan, where loss of function mutations in the P2RX2 gene lead to severe hearing loss across a lifetime (DFNA41 autosomal dominant progressive hearing loss). This developing understanding of purinergic regulation of hearing is establishing a translational pathway for identifying individuals 'at risk' of sensorineural hearing loss. Sensorineural hearing loss (SNHL) can result from exposure to excessive noise, ototoxic drugs, infection or progression with age. SNHL is associated with cochlear injury, including loss of sensory hair cells and primary auditory neurons. To date, there is no reliable treatment which can repair or prevent the cochlear injury and thus rescue cochlear function. We and others have identified adenosine receptor (AR) signalling pathways as important regulators of cochlear responses to injury. AR-based pharmacotherapies effective within a therapeutic time window have potential to limit the progression of the injury and reduce the need for prosthetic hearing devices. We have shown that administration of adenosine A 1 receptor (A 1 R) agonists in the post-exposure period can rescue the cochlea from acute noise-induced injury and prevent other forms of SNHL such as from cytotoxic drugs (cisplatin and aminoglycosides). As an alternative to the use of exogenous A 1 R agonists, we have recently identified a potent otoprotective paradigm based on increased A 1 R responsiveness to endogenous adenosine by inhibiting the molecular complex (RGS4-neurabin) that regulates A 1 R signalling. Our studies demonstrate that systemic or local administration of A 1 R agonists, adenosine kinase inhibitors or RGS4 inhibitors can rescue cochlear injury and hearing loss induced by acoustic overexposure, ototoxic drugs and ageing by reducing oxidative stress and apoptosis in cochlear tissues. Adenosine A 2A receptors may also be involved in cochlear protection, but as negative regulators of excitotoxic neural injury. Signalling pathways associated with adenosine receptors are thus emerging as effective targets for treatment of the most common forms of SNHL. Damaged and stressed cells in injured cochlear tissues release intracellular ATP that signals nearby supporting cells to start the clearance of apoptotic cells and repair the reticular lamina. This ATP-mediated process is crucial in preserving the integrity of the sensory epithelium but is potentially detrimental as it may promote sensory cell loss. However, the balance of purinergic P1 (adenosine) and P2 (ATP) receptors might be essential for cochlear reparative processes and homeostasis after injury. Using ototoxic aminoglycoside neomycin as an injury model, we have investigated the survival of cochlear sensory hair cells in different purinergic signalling environments. The organ of Corti explants from a postnatal P3 C57BL/6 mouse were exposed to neomycin (1 mM; 3 h) to induce a substantial reduction in the number of cochlear sensory hair cells. The effect of P2 receptor stimulation was investigated with the addition of ATP and the slowly hydrolysable analogue, ATPγS. P1 receptors were stimulated by adenosine (a broadly selective P1R agonist) and ADAC (a preferential A 1 R agonist). Neomycin-induced hair cell loss was unaffected by the addition of ATP, however ATPγS aggravated neomycin-induced loss of sensory hair cells. In contrast, adenosine and ADAC improved hair cell survival in organotypic tissue cultures of the mouse cochlea. These findings suggest that both P1 and P2 receptors are involved in cochlear response to injury; but may have opposite roles in hair cell survival. The enzymatic conversion of ATP to adenosine by ectonucleotidases could be a mechanism that prevents excessive hair cell loss during damage repair. Adenosine acts as a neurotransmitter at a range of purine (P1) receptors, including A 1 , A 2A , A 2B and A 3 . Activation of adenosine receptors is likely to be important for signalling between neurons and glial cells in the retina. The aim of this study was to characterize the location of the A 2A -receptor in the mammalian retina. Expression of the A 2A -receptor was evaluated using western blot and localisation studies were undertaken in the mouse, rat and human retina using immunohistochemistry and super resolution confocal microscopy. In the outer plexiform layer, punctate A 2A -receptor expression was found associated with rod but not cone photoreceptor terminals and was closely associated with horizontal, rod bipolar, and cone bipolar cells. This suggests a role for the A 2A -receptor in modulating vision under dim light conditions. In the inner retina, A 2A -receptor labelling was observed on calretinin-positive amacrine cells, was closely associated with rod and cone bipolar cell terminals and was expressed in retinal ganglion cells. In retinal glia, A 2A -receptor expression was observed in Müller cells but not astrocytes, consistent with a role in modulating neuronal support and tissue homeostasis. Additionally, the A 2A -receptor was expressed in microglia suggesting a role in local immune system regulation. In summary, adenosine provides input via the A 2A -receptor to neurons and glia in the retina, likely providing input to retinal neurons that modulate the dark-adapted visual response. These findings are consistent with the proposed functional role for this receptor in the retina determined from physiological studies in mice lacking A 2A -receptor expression. P2X7-receptors may contribute to retinal ganglion cell (RGC) death in glaucoma. We examined RGC function following acute intraocular pressure (IOP) elevation in aged C57BL/6 mice and P2X7-receptor knockout (P2X7-KO) mice. In 13-month-old C57BL/6 and P2X7-KO mice, the anterior chamber of one eye was cannulated to increase IOP to 50 mmHg for 30 min. The contralateral eye was cannulated without increasing IOP (sham). Three days following injury, RGC function was assessed via multielectrode array. Spontaneous activity was recorded and light-evoked responses were measured using 1 s full field flashes modulated between 0 and 1066 photoisomerisations/rod/s. Receptive fields were mapped by calculating the spike triggered average in response to a checkerboard stimulus. For analysis, cells were classified into ON, OFF, ON-OFF and non-responsive types based on peak firing during the fullfield stimuli. In wild-type mice there was a significant reduction in spontaneous activity and full-field-evoked spike rates for OFF RGCs from IOP eyes compared to sham eyes. These changes were subtype-specific as ON and ON-OFF cells showed no change. In P2X7-KO mice, OFF RGCs from IOP eyes also had significantly reduced spontaneous and light evoked firing. Additionally, ON RGCs from P2X7-KO IOP eyes showed a significant decrease in evoked spike rate compared to sham eyes. There were no effects of IOP on receptive field size. These results suggest that even a small, acute IOP injury can have lasting effects on RGC function, particularly affecting OFF-RGCs. In contrast to previous studies, P2X7-KO did not prevent RGC functional changes in increased IOP.
Multiple phagocytosis related factors underpin the pathogenesis of age-related macular degeneration 22, [1151] [1152] [1153] [1154] [1155] [1156] [1157] [1158] [1159] 2016) . By considering the carotid bodies, my presentation will describe novel purinergic P2X2/3 receptor mechanisms underpinning petrosal chemoreceptor neurone hyper-excitability as it contributes to hypertension, heart failure and breathing disorders in animals and humans. Our findings invoke a paradigm shift away from end organs to targeting visceral sensory neurones with selective small molecule P2X2/3 antagonists for the management of diseases in which autonomic imbalance prevails. These data may address the 20 year plus dearth of any new pharmacological approaches for the treatment of cardiorespiratory diseases. We acknowledge research support of Afferent Pharmaceuticals, British Heart Foundation-UK, Marsden Fund-NZ.
Non-hormonal male contraception using a combination of adrenoceptor and purinoceptor antagonists Sabatino Ventura Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
There are 85 million unwanted pregnancies worldwide each year. This equates to approximately one third of total births (W.H.O.). While present contraceptive methods are effective, there is clearly a need to develop additional methods of contraception for males, a market which is clearly lacking. Therapeutic targets for male contraception are associated with numerous problems due to their focus on disrupting spermatogenesis or hormonal mechanisms to produce dysfunctional sperm. This project describes the dual genetic deletion of α 1A -adrenoceptors and P2X1-purinoceptors in male mice thereby blocking sympathetically mediated sperm transport through the vas deferens during the emission phase of ejaculation. This modification produced 100% infertility without effects on sexual behaviour or function. Sperm taken from the cauda epididymides of double knockout mice were microscopically normal and motile. Furthermore, double knockout sperm were capable of producing normal offspring following intracytoplasmic sperm injection into wild type ova and implantation of the fertilized eggs into foster mothers. Blood pressure and baroreflex function was reduced in double knockout mice but no more than single knockout of α 1A -adrenoceptors alone. These results suggest that this autonomic method of male contraception appears free from major physiological and behavioural side effects. In addition, they provide conclusive proof of concept that pharmacological antagonism of the P2X1-purinoceptor and α 1A -adrenoceptor provides a safe and effective therapeutic target for a non-hormonal, readily reversible male contraceptive. A synthetic medicinal chemistry approach is currently under way to discover a suitable P2X1-purinoceptor antagonist to use in combination with tamsulosin for this purpose. P2X and P2Y receptors are present in mammalian macrophages, where they are associated with various conditions in humans and rodents including inflammation, chronic pain and cardiovascular disease. As such, these receptors are emerging therapeutic targets in human and veterinary medicine. The expression and function of purinergic receptors in humans and rodents has been well-studied, but corresponding data in dogs is lacking. Therefore, we aimed to identify and characterize endogenous P2 receptors in a canine macrophage model, DH82 cells. RT-PCR revealed expression of P2X1, P2X4, P2Y1, P2Y2, P2Y6 and P2Y11. Real-time measurements in Fura-2 AM-loaded cells, demonstrated that both ATP and UTP evoked calcium transients in a concentration-dependent fashion, which were impaired by 67% and 49% in the absence of extracellular calcium, respectively. The P2X4 antagonist, 5-BDBD, and the P2X4 positive modulator, ivermectin respectively partially impaired and potentiated ATP-induced calcium transients by 26% and 60%. Whilst the P2Y2 antagonist, AR-C118925, impaired both ATP-and UTP-induced calcium release by 59% and 92% respectively. Inhibitors of phospholipase C and inositol 1,4,5-trisphosphate receptors, U 73122 and 2-APB, completely impaired both ATP-and UTPinduced calcium release from intracellular stores. Together this data indicates P2Y2 and P2X4 are the major P2 subtypes present in canine DH82 macrophages. This identifies a new model for studying canine P2 receptor signalling in vitro, which will aid the development and validation of therapeutics targeting these receptors in dogs. BzATP), the P2Y1 agonist (ADP and MRS2365), and thrombin. All agonists released large numbers of MPs, in a rank order with thrombin > P2Y1 > P2X7. However, P2X7 agonists released a subpopulation of MPs in the large size range 200-600nm and which accumulated MitoTracker dye specific for mitochondria. Further, cryo-electron microscopy revealed that BzATP /ATP treated platelets released free mitochondria. In contrast, thrombin-treated platelets released fewer mitochondria, most of which were enclosed in a vesicular membrane, while P2Y1 agonists released almost no mitochondria. Agonists for P2X7 also released free mitochondria from platelets suspended in plasma (platelet rich plasma) and flow cytometry identified numbers of these in 13 normal donors as 1.8 ± 0.8 (SEM) x10 6 /mL plasma. In conclusion, platelets and PMP express P2X7 and activation of this receptor releases plasma microparticles, a subpopulation of which are free mitochondria which may exert inflammatory effects on vascular endothelium. Gliomas account for 80% of all brain cancers. These tumours predominantly manifest as high-grade glioblastomas that are vastly infiltrative and difficult to treat. Patients only survive for a median of 14-15 months post diagnosis. Despite advancements, current treatment is limited. Previous research has demonstrated the upregulation of a purinergic receptor, P2X7R, in human gliomas. P2X7R is known to be expressed on glioma cells and microglia within the glioma microenvironment. It is hypothesised that P2X7R contributes to tumour growth by activating immunosuppressive microglia and thus inhibiting P2X7R may prevent tumour proliferation. We sought to elucidate this by inhibiting P2X7R on both the U251 human glioblastoma cell line and human glioma samples obtained during surgical resection at the Royal Melbourne Hospital, Victoria, Australia. We treated U251 and human glioma cultures for 72 h with P2X7R antagonists: brilliant blue G (BBG), oxidized ATP (oATP) and AZ10606120. Cell counting via fluorescence confocal microscopy was conducted thereafter. We observed no significant reductions in tumour proliferation following P2X7R antagonism with oATP (250μM) in both U251 cells and human glioma samples; however, treatment with BBG (20 μM) significantly decreased cell count in U251 cells (P = 0.0079). Interestingly, tumour cell numbers were significantly lower than the controls in both U251 cells (P = 0.0156) and human glioma samples (P = 0.0476) treated with varying concentrations of AZ10606120. Our pilot results demonstrate a potential trophic role of P2X7R where its inhibition hinders glioma growth directly or through the inactivation of immunosuppressive microglia. This sheds new light on P2X7R as a therapeutic target for human gliomas.
Session 4: Inflammation and Immunity
New functions for the P2X7 receptor James S. Wiley Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia P2X7 receptors (previously termed P2Z receptors) entered the literature as a "permeabilising receptor" due to the unique action of its agonist, ATP, to increase the monovalent and divalent cation permeability of the cell by orders of magnitude. The massive K + efflux which occurs on opening of the monocyte-macrophage P2X7 channel/pore is critical for assembly of the NALP3 inflammasome, which in turn leads to processing and secretion of mature IL-1β and IL-18. However, other mediators of inflammation (such as mitochondria, which generate reactive oxygen species) may be involved. A second function seen on activation of the P2X7 receptor is blebbing and microvesiculation of the plasma membrane, and large numbers of microvesicles (termed microparticles, MP) have been found in blood plasma with sizes ranging from 40 nm to 500 nm. About half of these MPs have a platelet origin and have been shown to stimulate inflammation in diverse conditions such as septicaemia, influenza and multiple sclerosis, and autoimmune disease of uncertain aetiology. Recently our group has highlighted another function of the P2X7 receptor, namely a scavenging function in which cells expressing high levels of P2X7 can phagocytose apoptotic lymphocytes or neurons under serumfree conditions. Genetic studies have shown a P2X7-P2X4 variant which abolishes the phagocytic ability of this receptor and which is present in a large family with multiple sclerosis and is also overexpressed in an Australian cohort with primary progressive multiple sclerosis. A recent study of fresh microglia from brain surgical samples has confirmed a phagocytic role for microglial P2X7 with no evidence of a proinflammatory function, suggesting a primary scavenging role for this receptor in the central nervous system.
Purinergic signalling in the bladder in health and inflammation
Lu Liu, Zhinoos Taidi School of Medical Sciences, University of New South Wales, Kensington, New South Wales, Australia ATP released from parasympathetic motor neurons and from urothelial cells plays an important mechanosensory role in initiating micturition reflex. Altered ATP release and its effects in the bladder occur with ageing and in patients with overactive bladder and interstitial cystitis/bladder pain syndrome (IC/BPS). IC/BPS is a painful chronic bladder condition that predominantly affects women. The symptoms of IC/BPS are so debilitating that it can disrupt patients' ability to work and affect their sexual and social activities. Although the causes of IC/BPS are largely unknown, patients taking cyclophosphamide for chemotherapy can develop haemorrhagic cystitis. It is known that the metabolite acrolein is the causative factor of urotoxic side effects of cyclophosphamide. Studies in cyclophosphamide-induced animal models of haemorrhagic cystitis strongly support the role of P2X7 receptor (P2X7R) in the bladder inflammation. Using the pig bladder, we have recently developed an acrolein-induced ex-vivo cystitis model and inflammatory urothelial cell model. We found that perfusion of pig bladders with acrolein (0.05%) for 4 h resulted in increased apoptosis in the urothelium and suburothelial layers and complete loss of contractility of mucosal strips to acetylcholine, suggesting that acrolein severely damaged myofibroblasts and other contractile apparatus in the mucosa. Acrolein was also seen to disrupt cell integrity and increase permeability in cultured pig urothelial cells. The cytotoxic actions exerted by acrolein were abolished by the addition of P2X7R antagonist A804598 (10 μM). Our study provides strong evidence that P2X7R plays an important role in bladder inflammation and is a promising therapeutic target for treating bladder inflammation.
The role of vitamin D and P2X7R in multiple sclerosis
Veronica Voo Tsin Fong 1,2 , Mastura Monif and is mediated by the immune system. Previous studies have shown the presence of immune cell infiltrations, particularly T and B lymphocytes as well as microglia and monocytes in MS lesions. Due to the inflammatory nature of MS, a link between the ionotrophic purine P2X7 receptor (P2X7R) and MS lesion development is proposed. P2X7R is expressed on cells of the immune and nervous system involved in MS. Moreover, although vitamin D deficiency is associated with an increased risk of developing MS, its mechanism of action in the disease remains largely unknown. Our research aims to investigate whether vitamin D modulates P2X7R expressed on peripheral monocytes in MS. Peripheral monocytes were isolated from blood of MS patients (n = 5) and healthy volunteers (n = 7). P2X7R channel and pore function were investigated using confocal microscopy with fluorescence dyes Fluo-4 and ethidium bromide respectively. Immunohistochemistry using specific antibodies for P2X7R and CD11b (marker of activated monocytes) was used to examine P2X7R expression on monocytes. Preliminary results demonstrated the application of vitamin D to monocytes reduced P2X7R channel function (P = 0.04) but not pore function. Regarding P2X7R expression, vitamin D treatment appears to decrease its expression on monocytes (P = 0.05). Preliminary findings of our study showed potential therapeutic benefits of vitamin D in MS through modulation of P2X7R expressed on human monocytes. Further investigations are required to verify our findings.
Investigating the P2X7 receptor in a humanized mouse model of graft-versus-host disease
